Lantheus Medical chooses TrialStat for electronic data capture
Lantheus Medical Imaging, formerly Bristol Myers-Squibb Medical Imaging, has chosen TrialStat’s ClinicalAnalytics 4.0 (CA 4.0) for on-demand electronic data capture (EDC).
CA 4.0 enables clinical research organizations to deploy EDC twice as quickly as the industry average, accelerating their clinical research process, according to the Ottawa-based TrialStat.
Using CA 4.0, Lantheus can quickly change forms for protocol amendments, simply change workflows to accommodate new research groups and readily adapt the configurable EDC platform for different clinical research phases, as it extends the use of CA 4.0 for other trials, TrialStat said.
Lantheus’ U.S.-based, 30-site, 1,600-patient, post-market surveillance study using TrialStat’s EDC will take place over an eighteen-month period in 2008.
CA 4.0 enables clinical research organizations to deploy EDC twice as quickly as the industry average, accelerating their clinical research process, according to the Ottawa-based TrialStat.
Using CA 4.0, Lantheus can quickly change forms for protocol amendments, simply change workflows to accommodate new research groups and readily adapt the configurable EDC platform for different clinical research phases, as it extends the use of CA 4.0 for other trials, TrialStat said.
Lantheus’ U.S.-based, 30-site, 1,600-patient, post-market surveillance study using TrialStat’s EDC will take place over an eighteen-month period in 2008.